SALT LAKE CITY–(BUSINESS WIRE)–#BioSeeker–Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery programmable therapeutics, and point-of-care diagnostics, today announced an expansion of its Global Disease Atlas™ to include multiple hemorrhagic fever viruses. BioSeeker™, the company’s AI-powered discovery engine, has completed comprehensive genomic mapping across a suite of high-priority hemorrhagic fever viruses (HFV), which include Ebola virus, Marburg virus, Lassa Virus, Hanta Virus, Crimean-Congo hemorrhagic fever virus (CCHFV), and Rift Valley fever virus (RVFV).
BioSeeker scanned thousands of sequences across hemorrhagic fever pathogens to identify high-potential target regions that are essential for replication and remain stable across viral evolution. BioSeeker simultaneously screened against host genomes to predict off-target risks in the disease maps. These mapped “genomic vulnerabilities” provide the key blueprints for each disease to inform future therapeutic guide RNA design on the company’s CRISPR-based Programmable Target Ablation Platform (PTAP)™.
“Hemorrhagic fevers have long challenged researchers due to their genomic diversity and rapid evolution,” said Alison O’Mahony, VP of Therapeutic Research. “These mapped datasets illuminate key information to help us design, develop, and deploy safe and effective programmable therapeutics to reduce their high mortality rates and build global resilience.”
Hemorrhagic fevers represent some of the most devastating infectious diseases on earth. These pathogens can cause multi-system failure, severe internal bleeding, and mortality rates that can exceed 50-80% in some Ebola and Marburg outbreaks. Caused by rapidly mutating RNA viruses, they can evade immune defenses and undermine conventional vaccine or antiviral approaches. Outbreaks of Ebola, Marburg, CCHFV, and RVFV viruses often arise in regions where medical infrastructure is limited, forcing communities to fight an unrelenting cycle of vigilance and containment. By mapping and monitoring these pathogens through BioSeeker, Seek Labs is helping illuminate the genomic underpinnings of their persistence and evolution, laying the groundwork for future development of targeted, programmable therapeutics.
“By mapping viral families like Ebola, Marburg, and Crimean-Congo in such depth, BioSeeker is building the genomic intelligence foundation the world needs to respond faster to emerging hemorrhagic outbreaks,” said Jared Bauer, CEO. “With BioSeeker, we can now translate raw genomic data into actionable intelligence for the next era of global health preparedness.”
The inclusion of hemorrhagic fever viruses follows recent BioSeeker expansions across animal and human health threats. These disease maps form the backbone of the Global Disease Atlas, Seek Labs’ continually expanding reference library of genomic vulnerabilities across high-burden and emerging pathogens. By integrating hemorrhagic fever viruses into the Global Disease Atlas, Seek Labs compresses years of traditional genomic discovery into weeks, providing actionable intelligence that can be leveraged by governments, research institutions, and biotech collaborators to develop the next generation of countermeasures. Seek Labs invites collaboration from partners to translate these insights into next-generation solutions and strengthen readiness against emerging hemorrhagic threats.
About Seek Labs
At Seek Labs, we don’t wait for change—we build it. We’re pursuing the breakthroughs the world can’t wait for by developing programmable “seek-and-destroy” therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health.
Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.
Forward-Looking Statements and Regulatory Disclaimer
This press release contains forward-looking statements regarding the discovery, development, and potential applications of Seek Labs’ technologies. These statements are based on current expectations and are subject to risks and uncertainties, including those related to research, regulatory review, manufacturing, clinical development, and commercialization. Early-stage results and analyses may not predict future outcomes, and actual results may differ materially.
Contacts
Bridget Baldwin, Director of Communications, Seek Labs
[email protected]
